Professional Essentials · Free · No registration
Heart & Vessels in Rheumatic Disease
A clinical approach to cardiovascular symptoms, inflammation, heart failure, pulmonary hypertension and prevention.
Cardiovascular disease in rheumatology is a problem of mechanism as well as recognition. Inflammation, atherosclerosis, thrombosis, microvascular dysfunction, altered loading, fibrosis and treatment effects may coexist. Start by defining the cardiovascular syndrome and its urgency; then ask what evidence connects it to the systemic disease. A positive antibody, elevated troponin or abnormal scan contributes information, but none independently identifies the cause or selects immunosuppression.
1. Establish urgency before attribution
Ongoing severe chest pain, syncope, shock, new high-grade conduction disease, sustained arrhythmia or rapidly worsening breathlessness requires urgent assessment. Consider acute coronary disease, pulmonary embolism, acute aortic disease, tamponade and severe myocardial inflammation alongside infection. Tender chest-wall structures, familiar pleuritic symptoms or a previous reassuring investigation do not exclude a concurrent emergency.
For a stable patient, describe onset, trajectory and functional impact. Distinguish exertional pressure, positional pain, palpitations, orthopnea and reduced exercise tolerance. Record the actual prior tests and dates. A normal resting oxygen saturation does not measure cardiac output or exclude anemia; a preserved left ventricular ejection fraction does not establish normal cardiovascular function.
Persistent angina after nonobstructive coronary findings may still warrant evaluation of coronary function. The 2024 ESC chronic coronary guidance addresses angina and ischemia without obstructive arteries. Neither normal epicardial anatomy nor a microvascular abnormality establishes whether rheumatic inflammation is responsible. Connect the test result to the actual symptoms and a management decision.
Chest pain — full professional chapter →
Breathlessness — full professional chapter →
2. Interpret each measurement in context
Choose ECG, blood count, renal function, electrolytes, cardiac biomarkers and echocardiography according to the question. Echocardiography should assess both ventricles, valves, filling, pulmonary pressure probability and pericardial findings. Natriuretic peptides support assessment of cardiac stress; obesity, kidney dysfunction and rhythm affect interpretation. Persisting symptoms and discordant results deserve a revised explanation, not automatic reassurance.
Troponin indicates an injury signal, not an autoimmune etiology. In inflammatory myopathy, primary evidence demonstrates a possible skeletal-muscle contribution to troponin T; compare the assay, trajectory, troponin I when appropriate and clinical findings. This distinction must not delay evaluation of chest pain, syncope or electrical instability.
Screening and symptom investigation are different tasks. BSR recommends annual cardiac assessment in systemic sclerosis, typically including ECG, echocardiography, troponin and natriuretic peptides. This disease-specific schedule is not a universal annual panel for every rheumatic condition; new symptoms require assessment between scheduled visits.
Distinguishing cardiovascular mechanisms →
Interpreting cardiovascular biomarkers →
3. Separate inflammation from fluid and impaired filling
Pericarditis, pericardial effusion, tamponade and constriction are related but distinct. Establish compatible symptoms and supporting inflammatory, ECG or imaging evidence. An incidental effusion may reflect renal disease, venous pressure, infection or malignancy. Assess size, distribution, rate of change and hemodynamic consequences; fluid alone is not an instruction to increase steroids.
For appropriate uncomplicated inflammatory pericarditis, aspirin or an NSAID plus colchicine is usual first-line therapy. Review kidney/liver function, heart failure, bleeding and drug interactions. Recurrent or refractory disease requires confirmation of inflammation and a specialist steroid-sparing strategy; IL-1 therapy evidence from selected recurrent pericarditis does not establish control of associated lupus organ disease.
Unstable tamponade requires drainage without waiting for a steroid response. Constriction needs assessment of inflammatory reversibility versus fixed structural disease. Systemic sclerosis adds renal-crisis concerns to glucocorticoid decisions.
4. Define myocardial activity, damage and rhythm risk
Suspect myocardial involvement with compatible injury, ventricular dysfunction or new electrical disease. Evaluate ischemia, infection, toxicity and loading abnormalities alongside immune-mediated disease. Contemporary guidance uses CMR to characterize tissue and selected endomyocardial biopsy when histology can change treatment. A scar-like enhancement pattern is not synonymous with continuing steroid-responsive inflammation.
Hemodynamic and rhythm support proceed alongside etiologic investigation. Immune treatment depends on the systemic phenotype and evidence for active inflammation; many rheumatic myocarditis choices rely on observational data rather than comparative trials. Dangerous arrhythmia, shock or suspected treatable high-risk histology warrants an experienced multidisciplinary center.
Improved ejection fraction and normalized biomarkers do not independently remove residual rhythm risk. Arrange follow-up of function, symptoms and rhythm; restrict strenuous activity during active disease and individualize return after appropriate reassessment.
Myocardial inflammation and injury — full professional chapter →
5. Treat heart failure while clarifying its cause
Heart failure requires a compatible clinical syndrome with objective cardiac evidence; edema or preserved EF alone is insufficient. Review congestion, perfusion, valves, right-heart disease and filling pressures. The August 2026 ESC framework defines reduced EF below 50% and preserved EF at least 50%. Document numerical EF and the guideline used, because older trials and US classifications retain different categories.
Relieve congestion and implement phenotype-appropriate disease-modifying treatment after stabilization. Established HFrEF care combines renin–angiotensin/neprilysin-directed therapy, an evidence-based beta-blocker, an MRA and an SGLT2 inhibitor when eligible. The 2026 ACC HFpEF pathway also supports early SGLT2 inhibition and selected nonsteroidal MRA use. Kidney function, potassium, blood pressure and comorbidities determine safe implementation; drug classes are not automatically interchangeable.
After treatment changes, set an explicit plan for renal and electrolyte checks, symptoms, orthostatic blood pressure and volume assessment. Medication reconciliation should include drugs prescribed outside cardiology. A better EF does not justify unsupervised withdrawal of the regimen that accompanied improvement. Worsening congestion, low output or inability to tolerate therapy should prompt earlier specialist review.
6. Classify pulmonary hypertension before targeted therapy
Systemic sclerosis can produce PAH, lung-associated PH, left-heart disease or overlapping mechanisms. Echocardiography estimates probability; right-heart catheterization characterizes hemodynamics when the result guides management. Precapillary physiology is not synonymous with group 1 PAH. Evaluate lung disease and chronic thromboembolic obstruction as appropriate, including ventilation–perfusion imaging for the latter.
Confirmed PAH needs specialist risk assessment and combination treatment matched to severity; severe right-heart failure may require parenteral prostacyclin therapy. Do not transfer PAH regimens indiscriminately to other PH groups. Sotatercept has an adult group 1 PAH indication; its September 2026 label requires attention to hemoglobin, platelets, serious bleeding and hypersensitivity. New syncope or rapid deterioration overrides routine follow-up schedules.
7. Make prevention and follow-up explicit
Control systemic inflammation while addressing smoking, blood pressure, diabetes, lipids, physical activity and weight. The 2026 US dyslipidemia guideline uses PREVENT-ASCVD in eligible adults and recognizes chronic inflammatory conditions as risk enhancers. A prevention estimate does not investigate current chest pain. Established ASCVD requires its own secondary-prevention pathway.
Review NSAIDs, glucocorticoids, antithrombotics and other interacting treatments across specialties. Document the leading mechanism, unresolved alternatives, treatment target, relevant laboratory/rhythm monitoring and clinician responsible for results. Follow both measurable physiology and everyday function. Persistent limitation may reflect scar, lung or muscle disease even when inflammation improves; reassessment should explain that discrepancy before escalating treatment.
Selected sources
- ESC chronic coronary syndromes guideline, 2024.
- ESC myocarditis and pericarditis guideline, 2025.
- ACC myocarditis pathway, 2024: official key points.
- ACC pericarditis consensus, 2025: official publication summary.
- BSR systemic sclerosis guideline, 2024: executive summary.
- Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T, 2022.
- ESC heart-failure guideline, August 28, 2026: official summary.
- ACC HFrEF pathway, 2024: official key points.
- ACC HFpEF pathway, 2026: official key takeaways.
- ESC/ERS pulmonary hypertension guideline, 2022.
- WINREVAIR US prescribing information, revised September 2026.
- EULAR cardiovascular-risk management recommendations, 2022.
- ACC/AHA dyslipidemia guideline, March 2026: official summary.
Evidence is linked where it changes clinical decisions. Detailed chapters retain their individual access requirements.